Extraordinary General Meeting at Meda

Extraordinary General Meeting at Meda Meda AB will be holding an extraordinary general meeting in Göteborg on 30 June 1999. The meeting will consider the board's proposal for a directed issue of 2,515,963 A Series shares to Cross Pharma's owners which will be paid for by the transfer of all the shares in Cross Pharma Aktiebolag (556489-3948). Once the issue has been floated, the dilution effect will be around 51 per cent. The board's complete proposal together with documentation in accordance with Section 4 of the Swedish Companies Act, §§ 4 and 6, will be available from Wednesday, 23 June 1999, from Meda AB, Box 138, Stora Nygatan 17½ , SE-401 22 Göteborg and will be sent to shareholders who so request and supply their mailing address. An invitation to attend the extraordinary general meeting will be published in Svenska Dagbladet and the Swedish Official Gazette on Tuesday, 1 June. For further information, please contact Annette Johansson Public Relations Manager Phone +46 31-701 29 04 or +46 70-445 03 00 Meda develops profitable partnerships in the Nordic and Baltic areas in collaboration with international producers of pharmaceuticals, nutrition and medical device products. With our thorough knowledge and our expertise in marketing and sales, we offer benefits to the health and medical care sector at the same time as we promote our own and our partner's growth and development. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/06/01/19990601BIT00420/bit0001.doc http://www.bit.se/bitonline/1999/06/01/19990601BIT00420/bit0002.pdf

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.